Icaritin/Pexastimogene devacirepvec - Lees Pharmaceutical Holding/ Beijing Shenogen Pharma

Drug Profile

Icaritin/Pexastimogene devacirepvec - Lees Pharmaceutical Holding/ Beijing Shenogen Pharma

Alternative Names: SNG-162/JX-594; SNG-162/TG-6006

Latest Information Update: 07 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lees Pharmaceutical Holdings; Shenogen Pharma
  • Class Antineoplastics; Benzopyrans; Flavonoids; Oncolytic viruses; Phenyl ethers; Small molecules
  • Mechanism of Action Apoptosis stimulants; Estrogen receptor alpha modulators; Immunostimulants; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top